Stempoint Capital LP
NEW YORK, NY
$578m in 73 US stocks at the end of 30 June 2026. The top 10 are 41.2% of the money. It changed about 43.5% of the portfolio this quarter.
Value
$578m
Stocks
73
Top 10 share
41.2%
Turnover
43.5%
What changed this quarter
New
Bought for the first time this quarter.
- Kiniksa Pharmaceuticals InternationalKNSA2.3% of the fund
- First Tracks BiotherapeuticsTRAX2.2% of the fund
- Oruka TherapeuticsORKA1.9% of the fund
- Climb BioCLYM1.7% of the fund
- InflaRxIFRX1.3% of the fund
- Ovid TherapeuticsOVID1.1% of the fund
- EquilliumEQ1.1% of the fund
- Damora Therapeutics1.0% of the fund
- InventivaIVA0.9% of the fund
- Century TherapeuticsIPSC0.9% of the fund
- Aura BiosciencesAURA0.9% of the fund
- COMPASS PathwaysCMPS0.7% of the fund
- Avalyn PharmaAVLN0.7% of the fund
- Axsome TherapeuticsAXSM0.7% of the fund
- Monte Rosa TherapeuticsGLUE0.6% of the fund
- PersonalisPSNL0.6% of the fund
- Crescent BiopharmaCBIO0.6% of the fund
- Arrowhead PharmaceuticalsARWR0.6% of the fund
- Kodiak SciencesKOD0.5% of the fund
- Monopar TherapeuticsMNPR0.5% of the fund
- Rapport TherapeuticsRAPP0.5% of the fund
- Cue BiopharmaCUE0.4% of the fund
- Calcimedica0.2% of the fund
- Cellectar BiosciencesCLRB0.2% of the fund
- ProQR TherapeuticsPRQR0.1% of the fund
Added
Bought more of a stock they already held.
- Tango TherapeuticsTNGX6.6% of the fund+204%
- ErascaERAS5.0% of the fund+226%
- Tyra BiosciencesTYRA3.5% of the fund+64%
- Dianthus TherapeuticsDNTH3.4% of the fund+17%
- Alkermes plc.ALKS2.2% of the fund+54%
- Relmada TherapeuticsRLMD1.7% of the fund+22%
- Spruce BiosciencesSPRB0.4% of the fund+225%
Cut
Sold some of their stake.
- Abivax SAABVX6.5% of the fund-55%
- Revolution MedicinesRVMD5.2% of the fund-72%
- Enliven TherapeuticsELVN3.0% of the fund-52%
- Mineralys TherapeuticsMLYS2.8% of the fund-44%
- BiohavenBHVN2.7% of the fund-67%
- SurrozenSRZN2.4% of the fund-16%
- Scholar Rock HoldingSRRK2.3% of the fund-88%
- Praxis Precision MedicinesPRAX2.2% of the fund-67%
- Roivant SciencesROIV2.1% of the fund-55%
- BioAge LabsBIOA2.0% of the fund-31%
- CG OncologyCGON2.0% of the fund-61%
- ImmunovantIMVT1.8% of the fund-81%
- CelcuityCELC1.8% of the fund-18%
- Spyre TherapeuticsSYRE1.6% of the fund-68%
- Zura BioZURA1.4% of the fund-9%
- Amylyx PharmaceuticalsAMLX1.2% of the fund-71%
- Celldex TherapeuticsCLDX1.1% of the fund-65%
- Definium TherapeuticsDFTX1.1% of the fund-79%
- CytokineticsCYTK1.1% of the fund-71%
- EyePointEYPT0.8% of the fund-79%
- Assembly BiosciencesASMB0.8% of the fund-54%
- Whitehawk TherapeuticsWHWK0.8% of the fund-46%
- Xenon PharmaceuticalsXENE0.8% of the fund-73%
- uniQureQURE0.7% of the fund-44%
- MapLight TherapeuticsMPLT0.7% of the fund-47%
Sold out
Sold their entire stake.
- Syndax PharmaceuticalsSNDX-100%
- MBX BiosciencesMBX-100%
- Dyne TherapeuticsDYN-100%
- Edgewise TherapeuticsEWTX-100%
- Denali TherapeuticsDNLI-100%
- Nurix TherapeuticsNRIX-100%
- EvommuneEVMN-100%
- Faeth TherapeuticsFTH-100%
- Johnson & JohnsonJNJ-100%
- X4 PharmaceuticalsXFOR-100%
- VaxcytePCVX-100%
- InvivydIVVD-100%
- Jade BiosciencesJBIO-100%
- Twist BioscienceTWST-100%
- Avalo TherapeuticsAVTX-100%
- Ionis PharmaceuticalsIONS-100%
- Immunocore HldgsIMCR-100%
- Forte Biosciences-100%
- LipocineLPCN-100%
- Edwards LifesciencesEW-100%
- Capricor TherapeuticsCAPR-100%
- Sutro BiopharmaSTRO-100%
Holdings
- Abivax SAABVX
- Share
- 6.5%
- Value
- $38m
- Shares
- 283,657
-55%
- First Tracks BiotherapeuticsTRAX
- Share
- 2.2%
- Value
- $13m
- Shares
- 622,723
New
- Damora Therapeutics
- Share
- 1.0%
- Value
- $6m
- Shares
- 216,194
New
- Avalyn PharmaAVLN
- Share
- 0.7%
- Value
- $4m
- Shares
- 118,000
New
- Structure TherapeuticsGPCR
- Share
- 0.4%
- Value
- $2m
- Shares
- 38,178
-90%
- Helix Acquisition Corp. IIIHLXC
- Share
- 0.3%
- Value
- $2m
- Shares
- 171,671
-72%
- Calcimedica
- Share
- 0.2%
- Value
- $1m
- Shares
- 1,244,864
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Tango TherapeuticsTNGX | 6.6% | $38m | 1,223,019 | +204% |
| Abivax SAABVX | 6.5% | $38m | 283,657 | -55% |
| Revolution MedicinesRVMD | 5.2% | $30m | 159,943 | -72% |
| ErascaERAS | 5.0% | $29m | 1,565,913 | +226% |
| Tyra BiosciencesTYRA | 3.5% | $20m | 632,754 | +64% |
| Dianthus TherapeuticsDNTH | 3.4% | $20m | 200,851 | +17% |
| Enliven TherapeuticsELVN | 3.0% | $18m | 346,914 | -52% |
| Mineralys TherapeuticsMLYS | 2.8% | $16m | 602,686 | -44% |
| BiohavenBHVN | 2.7% | $16m | 1,064,200 | -67% |
| SurrozenSRZN | 2.4% | $14m | 602,798 | -16% |
| Kiniksa Pharmaceuticals InternationalKNSA | 2.3% | $13m | 209,234 | New |
| Scholar Rock HoldingSRRK | 2.3% | $13m | 239,146 | -88% |
| Alkermes plc.ALKS | 2.2% | $13m | 248,015 | +54% |
| First Tracks BiotherapeuticsTRAX | 2.2% | $13m | 622,723 | New |
| Praxis Precision MedicinesPRAX | 2.2% | $12m | 37,243 | -67% |
| Roivant SciencesROIV | 2.1% | $12m | 348,408 | -55% |
| BioAge LabsBIOA | 2.0% | $11m | 464,171 | -31% |
| CG OncologyCGON | 2.0% | $11m | 159,349 | -61% |
| Oruka TherapeuticsORKA | 1.9% | $11m | 116,461 | New |
| ImmunovantIMVT | 1.8% | $11m | 276,527 | -81% |
| CelcuityCELC | 1.8% | $10m | 98,203 | -18% |
| Relmada TherapeuticsRLMD | 1.7% | $10m | 1,460,093 | +22% |
| Climb BioCLYM | 1.7% | $10m | 742,745 | New |
| Spyre TherapeuticsSYRE | 1.6% | $9m | 106,926 | -68% |
| Zura BioZURA | 1.4% | $8m | 1,368,215 | -9% |
| InflaRxIFRX | 1.3% | $7m | 3,228,255 | New |
| Amylyx PharmaceuticalsAMLX | 1.2% | $7m | 384,304 | -71% |
| Celldex TherapeuticsCLDX | 1.1% | $7m | 178,412 | -65% |
| Ovid TherapeuticsOVID | 1.1% | $7m | 2,417,283 | New |
| EquilliumEQ | 1.1% | $6m | 2,016,607 | New |
| Definium TherapeuticsDFTX | 1.1% | $6m | 137,124 | -79% |
| CytokineticsCYTK | 1.1% | $6m | 75,603 | -71% |
| Damora Therapeutics | 1.0% | $6m | 216,194 | New |
| InventivaIVA | 0.9% | $5m | 1,426,320 | New |
| Century TherapeuticsIPSC | 0.9% | $5m | 2,146,182 | New |
| Aura BiosciencesAURA | 0.9% | $5m | 714,280 | New |
| EyePointEYPT | 0.8% | $5m | 338,471 | -79% |
| Assembly BiosciencesASMB | 0.8% | $5m | 170,378 | -54% |
| Whitehawk TherapeuticsWHWK | 0.8% | $5m | 1,021,037 | -46% |
| Xenon PharmaceuticalsXENE | 0.8% | $5m | 76,075 | -73% |
| uniQureQURE | 0.7% | $4m | 88,115 | -44% |
| COMPASS PathwaysCMPS | 0.7% | $4m | 284,769 | New |
| Avalyn PharmaAVLN | 0.7% | $4m | 118,000 | New |
| MapLight TherapeuticsMPLT | 0.7% | $4m | 106,906 | -47% |
| AlumisALMS | 0.7% | $4m | 135,736 | -70% |
| Axsome TherapeuticsAXSM | 0.7% | $4m | 15,375 | New |
| Monte Rosa TherapeuticsGLUE | 0.6% | $4m | 153,544 | New |
| Acadia PharmaceuticalsACAD | 0.6% | $4m | 143,167 | -70% |
| Solid BiosciencesSLDB | 0.6% | $4m | 358,780 | -8% |
| PersonalisPSNL | 0.6% | $3m | 247,783 | New |
| Crescent BiopharmaCBIO | 0.6% | $3m | 182,382 | New |
| Arrowhead PharmaceuticalsARWR | 0.6% | $3m | 39,198 | New |
| Kodiak SciencesKOD | 0.5% | $3m | 75,872 | New |
| PharvarisPHVS | 0.5% | $3m | 80,907 | -53% |
| Monopar TherapeuticsMNPR | 0.5% | $3m | 30,125 | New |
| Rapport TherapeuticsRAPP | 0.5% | $3m | 66,582 | New |
| NewAmsterdam PharmaNAMS | 0.5% | $3m | 77,589 | -79% |
| Sionna TherapeuticsSION | 0.5% | $3m | 59,426 | -19% |
| Arcutis BiotherapeuticsARQT | 0.4% | $3m | 98,945 | -88% |
| C4 TherapeuticsCCCC | 0.4% | $2m | 523,648 | -42% |
| Spruce BiosciencesSPRB | 0.4% | $2m | 41,388 | +225% |
| Cue BiopharmaCUE | 0.4% | $2m | 66,995 | New |
| Structure TherapeuticsGPCR | 0.4% | $2m | 38,178 | -90% |
| Protagonist TherapeuticsPTGX | 0.3% | $2m | 16,303 | -89% |
| Helix Acquisition Corp. IIIHLXC | 0.3% | $2m | 171,671 | -72% |
| BiodesixBDSX | 0.3% | $2m | 70,000 | -50% |
| Tenax TherapeuticsTENX | 0.2% | $1m | 96,273 | -74% |
| SAB BiotherapeuticsSABS | 0.2% | $1m | 342,631 | -54% |
| Calcimedica | 0.2% | $1m | 1,244,864 | New |
| LB PharmaceuticalsLBRX | 0.2% | $1m | 31,785 | -68% |
| Cellectar BiosciencesCLRB | 0.2% | $986,728 | 354,938 | New |
| ProQR TherapeuticsPRQR | 0.1% | $801,760 | 431,054 | New |
| Vistagen TherapeuticsVTGN | <0.1% | $17,276 | 616,749 | -50% |
Options (11)
- PersonalisPSNL
- Type
- Call
- Value
- $810,750
- Contracts
- 470,000
- BiohavenBHVN
- Type
- Call
- Value
- $525,000
- Contracts
- 500,000
- Spdr Series TrustXBI
- Type
- Put
- Value
- $400,000
- Contracts
- 250,000
- AstrazenecaAZN
- Type
- Call
- Value
- $180,000
- Contracts
- 25,000
- Spdr Series TrustXBI
- Type
- Call
- Value
- $178,000
- Contracts
- 400,000
- Tango TherapeuticsTNGX
- Type
- Call
- Value
- $175,000
- Contracts
- 100,000
- Revolution MedicinesRVMD
- Type
- Put
- Value
- $127,500
- Contracts
- 30,000
- ErascaERAS
- Type
- Put
- Value
- $90,000
- Contracts
- 200,000
- ARK ETF TRARKG
- Type
- Put
- Value
- $75,000
- Contracts
- 100,000
- Roivant SciencesROIV
- Type
- Put
- Value
- $40,000
- Contracts
- 100,000
- AmgenAMGN
- Type
- Put
- Value
- $15,000
- Contracts
- 15,000
| Company | Type | Value | Contracts |
|---|---|---|---|
| PersonalisPSNL | Call | $810,750 | 470,000 |
| BiohavenBHVN | Call | $525,000 | 500,000 |
| Spdr Series TrustXBI | Put | $400,000 | 250,000 |
| AstrazenecaAZN | Call | $180,000 | 25,000 |
| Spdr Series TrustXBI | Call | $178,000 | 400,000 |
| Tango TherapeuticsTNGX | Call | $175,000 | 100,000 |
| Revolution MedicinesRVMD | Put | $127,500 | 30,000 |
| ErascaERAS | Put | $90,000 | 200,000 |
| ARK ETF TRARKG | Put | $75,000 | 100,000 |
| Roivant SciencesROIV | Put | $40,000 | 100,000 |
| AmgenAMGN | Put | $15,000 | 15,000 |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 86.1% since 30 June 2025.
Where the money is
Health care91.6%
Financial services0.3%
Other8.1%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.